ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
Zevra Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Market Cap | $603.34M | $197.05M |
| Enterprise Value | $381.77M | $106.56M |
| PE Ratio | 10.92 | 20.52 |
| PS Ratio | 4.43 | 3.93 |
| PB Ratio | 2.77 | 2.14 |
| P/TBV Ratio | 2.91 | 2.46 |
| P/FCF Ratio | 18.49 | 18.25 |
| P/OCF Ratio | 18.06 | 13.78 |
Enterprise value
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 2.81 | 2.69 |
| EV / EBITDA | 4.55 | 14.86 |
| EV / EBIT | 4.63 | 19.00 |
| EV / FCF | 11.70 | 21.02 |
Income (trailing twelve months)
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Revenue | $136.07M | $57.94M |
| Gross Profit | $129.89M | $90.47M |
| Operating Income | $82.38M | -$21.44M |
| Pretax Income | $69.29M | -$14.45M |
| Net Income | $58.26M | -$22.46M |
| EBITDA | $83.87M | -$16.91M |
| EPS (Diluted) | $0.93 | -$0.83 |
Margins
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 95.5% | 52.3% |
| Operating Margin | 60.5% | -44.5% |
| Pretax Margin | 50.9% | -13.0% |
| Profit Margin | 42.8% | -39.2% |
| EBITDA Margin | 61.6% | -31.3% |
| FCF Margin | 24.0% | -8.85% |
Returns
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 34.8% | -53.1% |
| Return on Assets (ROA) | 20.8% | -41.0% |
| Return on Capital Employed (ROCE) | 32.4% | -37.8% |
Growth
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 119.4% | 6.01% |
| Net Income Growth (YoY) | 2103.6% | -37.7% |
| Revenue Growth (3Y CAGR) | 118.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 51.6% | 6.42% |
Balance sheet
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $221.57M | $62.42M |
| Total Debt | $0 | $120.13M |
| Net Cash (Debt) | $221.57M | $15.68M |
| Net Cash Per Share | $3.73 | $0.65 |
| Equity (Book Value) | $217.65M | $48.79M |
| Book Value Per Share | $3.67 | $1.36 |
| Tangible Book Value | $207.16M | $23.06M |
| Working Capital | $202.67M | $75.77M |
Financial position
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.17 | 3.30 |
| Quick Ratio | 4.56 | 2.39 |
| Debt / Equity | 0.00 | 0.51 |
| Debt / EBITDA | 0.00 | 3.35 |
| Debt / FCF | 0.00 | 5.05 |
| Net Debt / EBITDA | -2.64 | 2.22 |
| Interest Coverage | 14.43 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $33.40M | -$12.35M |
| Capital Expenditures | -$775.00K | -$1.06M |
| Free Cash Flow | $32.62M | -$20.28M |
| FCF Per Share | $0.55 | -$0.41 |
Efficiency
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.49 | 0.38 |
| Inventory Turnover | 3.47 | 2.67 |
| Revenue Per Employee | $2.23M | $398.96K |
| Profits Per Employee | $955.13K | -$732.08K |
| Employee Count | 61 | 73 |
Dividends and yields
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 9.66% | -21.2% |
| FCF Yield | 5.41% | -7.64% |
Shares
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 59,383,800 | 59,128,900 |
| Shares Change (YoY) | 11.6% | 11.1% |
| Shares Change (QoQ) | 0.38% | 0.54% |
| Float | 58,683,800 | 48,744,500 |
| Shares Held by Insiders | 1.18% | 11.8% |
| Shares Held by Institutions | 78.5% | 59.4% |
Taxes
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Income Tax | $11.02M | $91.50K |
| Effective Tax Rate | 15.9% | 20.6% |
Scores
| Measure | Zevra Therapeutics | Industry median |
|---|---|---|
| Graham Number | $8.76 | $17.36 |
| Graham Upside | -13.8% | -45.5% |
| Altman Z-Score | 4.67 | 0.10 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Zevra Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.